Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nanologica AB ( (SE:NICA) ) has issued an announcement.
Nanologica AB reported an increase in net sales for the second quarter of 2025, despite a continued operating loss. The company received significant orders for its NLAB Saga® product from new customers in China and the US, marking its entry into the North American market. Additionally, Flerie Invest AB increased its ownership in Nanologica, prompting a mandatory bid offer, which the board advised shareholders to reject.
More about Nanologica AB
Nanologica AB operates in the pharmaceutical industry, focusing on the development and commercialization of nanoporous silica for drug delivery and chromatography applications. The company is expanding its market presence with recent orders from new customers in China and the US.
Average Trading Volume: 314,841
Current Market Cap: SEK96.31M
For a thorough assessment of NICA stock, go to TipRanks’ Stock Analysis page.